Skip to main content

3 faculty named Distinguished Professors

By University Honors and Awards

March 18, 2024

Indiana University has named three faculty members as Distinguished Professors, the most prestigious appointment offered to honor faculty whose outstanding scholarship, artistic or literary distinction or other achievements have won significant recognition by peers.

Since its creation in 1953, 257 IU faculty members have earned this honor. Distinguished Professor appointees for 2024 are:

Chandy C. John

Dr. Chandy John has held several preeminent positions at Indiana University since 2015, including the Ryan White Professor of Pediatrics, the director of the Ryan White Center for Pediatric Infectious Disease and Global Health at the IU School of Medicine, and professor of medicine, microbiology and immunology.

Over his 30-year career, John’s research has focused on global health, with a particular focus on malaria. He is considered to be a world leader for his work in Uganda, where he has conducted groundbreaking studies on the sequelae of malaria and for providing international guidance for the treatment of sickle cell disease — a genetic disorder of increased frequency in Africa, particularly in regions with high rates of malaria.

Gerard N. Magliocca

Gerard N. Magliocca, the Samuel R. Rosen Professor of Law at the Indiana University Robert H. McKinney School of Law, has a more than two-decade-long career marked by scholarly excellence and notable contributions to the field of law.

He is recognized as the world’s leading voice on the original meaning and application of Section 3 of the 14th Amendment to the U.S. Constitution. With a substantial publication record and numerous citations, which include five books and 30 articles across leading law reviews, Magliocca is known as one of the most original and productive scholars of his generation because of his insights into the relationship between law, history and political science.

Adam Zlotnick

As a member of the IU community since 2008, professor Adam Zlotnick takes scientific discovery from the bench to the bedside in a manner that has important and positive human health benefits. His research has advanced several novel antiviral drug candidates, one of which advanced to Phase Two clinical trials and proved to be highly effective and safe in the treatment of hepatitis B.

He has over 140 publications that have generated over 12,000 citations and 12 patents, 11 of which were filed while at IU, underpinning his international reputation and his ability to obtain significant public funding, including from the National Institutes of Health, and private funding for his research efforts. His research and leadership have led to the launch of two biotech companies, one of which is now a public company recognized as the leader in hepatitis B virus therapeutics.